---
title: "Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278763205.md"
datetime: "2026-03-11T18:07:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278763205.md)
  - [en](https://longbridge.com/en/news/278763205.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278763205.md)
---

# Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026

March 11 (Reuters) - BridgeBio Pharma Inc (BBIO.O) : \* BBP-418 DEMONSTRATES CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN PHASE 3 FORTIFY INTERIM ANALYSIS IN LGMD2I/R9 \* BRIDGEBIO PHARMA INC - TO SUBMIT NDA FOR BBP-418 TO FDA IN H1 2026 \* BRIDGEBIO PHARMA INC - BBP-418 WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO PLACEBO

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated by Analysts at Royal Bank Of Canada](https://longbridge.com/en/news/282203534.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [ZAWYA: CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly](https://longbridge.com/en/news/282695762.md)
- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)
- [FDA issues complete response letter to Replimune’s RP1 for melanoma](https://longbridge.com/en/news/282511585.md)